Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Baggott

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|September 30, 2025
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucelLauren E Appell, Christina Baggott, Khanh Nguyen, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Frontiers in Immunology|November 15, 2023
Mediport use as an acceptable standard for CAR T cell infusionMaya Eylon, Snehit Prabhu, Samuel John, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|September 30, 2025
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucelLauren E Appell, Christina Baggott, Khanh Nguyen, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Frontiers in Immunology|November 15, 2023
Mediport use as an acceptable standard for CAR T cell infusionMaya Eylon, Snehit Prabhu, Samuel John, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Pageof 10